Methylation of the DPYD Promoter: An Alternative Mechanism for Dihydropyrimidine Dehydrogenase Deficiency in Cancer Patients
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Purpose: Dihydropyrimidine dehydrogenase (DPD) deficiency, a known pharmacogenetic syndrome associated with 5-fluorouracil (5-FU) toxicity, has been detected in 3% to 5% of the population. Genotypic studies have identified >32 sequence variants in the DPYD gene; however, in a number of cases, sequence variants could not explain the molecular basis of DPD deficiency. Recent studies in cell lines indicate that hypermethylation of the DPYD promoter might down-egulate DPD expression. The current study investigates the role of methylation in cancer patients with an unexplained molecular basis of DPD deficiency. Experimental Design: DPD deficiency was identified phenotypically by both enzyme assay and uracil breath test, and genotypically by denaturing high-performance liquid chromatography. The methylation status was evaluated in PCR products (209 bp) of bisulfite-modified DPYD promoter, using a novel denaturing high-performance liquid chromatography method that distinguishes between methylated and unmethylated alleles. Clinical samples included five volunteers with normal DPD enzyme activity, five DPD-deficient volunteers, and five DPD-deficient cancer patients with a history of 5-FU toxicity. Results: No evidence of methylation was detected in samples from volunteers with normal DPD. Methylation was detected in five of five DPD-deficient volunteers and in three of five of the DPD-deficient cancer patient samples. Of note, one of the two samples from patients with DPD-deficient cancer with no evidence of methylation had the mutation DPYD*2A, whereas the other had DPYD*13. Discussion: Methylation of the DPYD promoter region is associated with down-regulation of DPD activity in clinical samples and should be considered as a potentially important regulatory mechanism of DPD activity and basis for 5-FU toxicity in cancer patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, methylation of the DPYD promoter region can reduce the activity of DPD in clinical samples [99].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [99]
Citations
Cites
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
MethyLight: a high-throughput assay to measure DNA methylation
Eads, C. A. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.8.e32 · Cited by 1,424
Relevance of DNA methylation in the management of cancer
Esteller, M. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01115-x · Cited by 329
Identification and resolution of artifacts in bisulfite sequencing
Warnecke, P. M., Stirzaker, C., Song, J., Grunau, C., Melki, J. R., & Clark, S. J. (2002) · Methods · doi:10.1016/s1046-2023(02)00060-9 · Cited by 302
DNA methylation and gene silencing in cancer: which is the guilty party?
Clark, S. J., & Melki, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205598 · Cited by 287
Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency
Van Kuilenburg, A. B. P., Vreken, P., Abeling, N. G. G. M., Bakker, H. D., Meinsma, R., Van Lenthe, H., De Abreu, R. A., Smeitink, J. A. M., Kayserili, H., Apak, M. Y., et al. (1999) · Human Genetics · doi:10.1007/pl00008711 · Cited by 282
Kuilenburg, A. B. P., Muller, E. W., Haasjes, J., Meinsma, R., Zoetekouw, L., Waterham, H. R., Baas, F., Richel, D. J., & Gennip, A. H. (2001) · PubMed · Cited by 253
Ezzeldin, H., & Diasio, R. (2004) · Clinical Colorectal Cancer · doi:10.3816/ccc.2004.n.018 · Cited by 169
Self-citationJohnson, M. R., & Diasio, R. B. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00011-x · Cited by 151
Self-citationThe impact of chromatin in human cancer: linking DNA methylation to gene silencing
Ballestar, E., & Esteller, M. (2002) · Carcinogenesis · doi:10.1093/carcin/23.7.1103 · Cited by 143
Cited by
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 778
Schwab, M., Zanger, U. M., Marx, C., Schaeffeler, E., Klein, K., Dippon, J., Kerb, R., Blievernicht, J., Fischer, J., Hofmann, U., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4182 · Cited by 393
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Zhang, X., Soong, R., Wang, K., Li, L., Davie, J. R., Guarcello, V., & Diasio, R. B. (2007) · Biochemistry and Cell Biology · doi:10.1139/o07-009 · Cited by 21
Self-citation
Metadata
- Authors
- Ezzeldin, H. H., Lee, A. M., Mattison, L. K., & Diasio, R. B.
- Affiliations
- University of Alabama at Birmingham (US)
- Venue
- Clinical Cancer Research
- Published
- 2005-12-15
- Volume
- 11
- Issue
- 24
- Pages
- 8699-8705
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2149894474
- Cited by
- 96
- References
- 26
- Citations by year
- 2026: 2 · 2024: 2 · 2023: 1 · 2022: 6 · 2021: 4 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 5 · 2013: 6 · 2012: 5
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Alabama at Birmingham
- National Cancer Institute (CA-62164, CA85381, R01CA062164, R01CA085381)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Hematology › Methemoglobinemia and Tumor Lysis Syndrome
- Keywords
- dihydropyrimidine dehydrogenase deficiency, epigenetic silencing, 5-fluorouracil toxicity, pharmacogenetics, cancer patients, DPYD*2A, gene expression regulation
- MeSH terms
- Adult, Antimetabolites, Antineoplastic, Chromatography, High Pressure Liquid, Female, Fluorouracil, Genotype, Humans, Male, Middle Aged, Mutation, Neoplasms, Nucleic Acid Denaturation, Phenotype, Promoter Regions, Genetic, Down-Regulation, CpG Islands, DNA Methylation, Dihydrouracil Dehydrogenase (NADP), Dihydropyrimidine Dehydrogenase Deficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methylation of the DPYD Promoter: An Alternative Mechanism for Dihydropyrimidine Dehydrogenase Deficiency in Cancer Patients. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-1520
- The paper
- Ezzeldin, H. H., Lee, A. M., Mattison, L. K., & Diasio, R. B. (2005). Methylation of the DPYD Promoter: An Alternative Mechanism for Dihydropyrimidine Dehydrogenase Deficiency in Cancer Patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-1520
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.